Form 4: Natera Co-Founder Sells Shares Under 10b5-1 Plans

Natera, Inc. Co-Founder and Director Jonathan Sheena reported sales of 4,960 shares of common stock through pre-arranged Rule 10b5-1 trading plans.

Summary

• Jonathan Sheena, Co-Founder and Director of Natera, Inc., reported the sale of 4,960 shares of common stock.
• On November 7, 2025, 3,070 shares were sold directly at weighted average prices ranging from $190.3276 to $198.38.
• These direct sales were executed under a Rule 10b5-1 trading plan adopted on December 11, 2024.
• On November 11, 2025, an additional 1,890 shares were sold indirectly through the Caraluna 1 Trust (900 shares) and Caraluna 2 Trust (990 shares) at weighted average prices ranging from $206.8622 to $209.2844.
• The indirect sales were executed under a separate Rule 10b5-1 trading plan adopted on June 7, 2024.
• Following these transactions, Jonathan Sheena directly beneficially owns 232,660 shares and indirectly beneficially owns 25,282 shares through each of the Caraluna 1 Trust and Caraluna 2 Trust.

Sentiment

Score: 6

Explanation: The sales are routine insider transactions executed under pre-established 10b5-1 plans, which generally reduces the negative sentiment often associated with insider selling. The sales occurred at relatively high stock prices.

Positives

• The sales were conducted under Rule 10b5-1 trading plans, indicating pre-scheduled transactions rather than immediate reactions to new, non-public information.
• The sales occurred at relatively high price points, ranging from $190.00 to $209.29 per share.

Negatives

• Insider selling, even under a 10b5-1 plan, reduces the insider's direct stake in the company, which can sometimes be perceived negatively by investors.
• The total number of shares sold (4,960) represents a reduction in the reporting person's overall beneficial ownership.

Risks

• No specific risks are mentioned in this Form 4 filing. However, significant or continuous insider selling, even under 10b5-1 plans, could potentially be interpreted by the market as a lack of confidence, which is a general market risk.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it primarily reports past insider transactions.

Industry Context

This Form 4 filing reports routine insider stock sales under pre-arranged trading plans. Such transactions are common across industries for executives managing personal finances and diversifying portfolios, and do not inherently reflect specific industry trends or competitive positioning for Natera, Inc.

Comparison to Industry Standards

• This filing details insider stock sales executed under Rule 10b5-1 trading plans. This practice is a standard and widely accepted method for corporate insiders to sell company stock while mitigating concerns about trading on material non-public information.
• Many executives at comparable biotechnology and diagnostic companies utilize similar plans for personal financial management.
• The prices at which the shares were sold reflect market conditions at the time of the transactions and are not directly comparable to specific project results or company performance benchmarks without further context.

Related Party Transactions

• Sales of Natera, Inc. common stock were made indirectly through the Caraluna 1 Trust and Caraluna 2 Trust, which are related parties to the reporting person, Jonathan Sheena.

Stakeholder Impact

• Shareholders: The sale of shares by a co-founder and director could be perceived as a slight negative signal, though mitigated by the 10b5-1 plans. It reduces the insider's direct alignment with future stock price appreciation.
• Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated by this routine insider transaction report.

Next Steps

• No specific future actions or milestones are mentioned in this Form 4 filing.

Key Dates

Recommendation

This Form 4 filing reports routine insider sales executed under pre-established 10b5-1 trading plans. While insider selling can sometimes be a negative signal, the pre-planned nature of these transactions significantly mitigates concerns about immediate negative implications for the company's outlook. The sales occurred at strong price points. Without additional fundamental or technical analysis, this specific filing alone does not provide sufficient new information to warrant a change from a 'hold' position, as it reflects personal financial planning rather than a shift in corporate strategy or performance.

Keywords

Natera, NTRA, Jonathan Sheena, insider trading, Form 4, stock sale, 10b5-1 plan, beneficial ownership, director, co-founder